Copyright © Inderes 2011 - present. All rights reserved.
  • Seneste
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Udbyttekalender
    • Research
    • Artikler
    • Transskriptioner
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team
Analytikerkommentar

Aiforia raised 4.2 MEUR in a directed share issue

Aiforia Technologies

Oversigt

  • Aiforia raised approximately 4.2 MEUR through a directed share issue to support its growth strategy, increasing its number of shares by 6.3%.
  • The share issue was conducted at a subscription price of EUR 2.106 per share, representing a typical 10% discount to the pre-issue closing price of EUR 2.34.
  • The offering was smaller and occurred earlier than anticipated, slightly impacting forecasts, but it extends Aiforia's cash sufficiency to the last quarter of 2026.
  • The share issue was expected and necessary, with minor negative effects on valuation, reducing short-term financing risks.

This content is generated by AI. You can give feedback on it in the Inderes forum.

Translation: Original published in Finnish on 12/11/2025 at 8:31 am EET.

Aiforia announced on Wednesday evening that it had successfully completed a directed share issue, through which the company raised gross proceeds of around 4.2 MEUR to support the financing of its growth strategy. The share issue was carried out in an accelerated bookbuilding process, and as a result, the number of shares in the company will increase by 6.3%. The issue was expected, although it took place slightly earlier than we predicted, was smaller, and at a slightly lower valuation. The share issue has a minor impact on our forecasts, and we will update our estimates to reflect the increased number of shares and strengthened cash position no later than in connection with the H2 report.

The directed share issue was expected and necessary for financing the company's growth strategy

Aiforia issued 2 million new shares in the offering at a subscription price of EUR 2.106 per share. The share issue increases the company's number of shares by 6.3%, and its pricing corresponded to a typical 10% discount to the closing price (EUR 2.34) before the issue. The share issue came as no surprise to us, as we had already predicted that Aiforia would need additional funding to implement its growth strategy. Aiforia has also recently implemented cost savings to limit its funding needs.

Before the share issue, we estimated that the company's cash would be sufficient until approximately Q2/2026, and we assumed the company would raise a total of 20 MEUR in new equity in 2026 and 2027. The now completed 4.2 MEUR offering is smaller than our estimated 10 MEUR one-off item and was realized earlier than our forecast. With the support of the completed share issue, Aiforia's cash is estimated to be sufficient until around the last quarter of 2026.

Our estimates included share issues at a price of EUR 2.36 per share (the share price level of the previous report published on November 18, 2025, minus 10%), in relation to which the issue was carried out at a price some 11% lower. The share issue thus has only slightly negative effects on our valuation in this respect, and its realization at the same time slightly reduces the company's short-term financing risks. We will incorporate the initially mild effects of the share issue into our forecasts no later than in connection with the company's financial statement release.

 

Aiforia Technologies equips pathologists and researchers in preclinical and clinical laboratories with software to translate images into discoveries, decisions and diagnoses. The company's products and services are used for medical image analysis, across a variety of fields such as oncology and neuroscience. Aiforia Technologies is headquartered in Finland.

Læs mere på virksomhedsside

Key Estimate Figures19.11.2025

202425e26e
Omsætning2,93,35,1
vækst-%18,9 %16,4 %55,0 %
EBIT (adj.)-12,2-10,9-8,6
EBIT-% (adj.)-427,8 %-328,4 %-167,6 %
EPS (adj.)-0,41-0,39-0,28
Udbytte0,000,000,00
Udbytte %
P/E (adj.)neg.neg.neg.
EV/EBITDAneg.neg.neg.

Forumopdateringer

I morgen ser det ud til, at Siemens Healthineers har en form for regnskabsaflæggelse, generalforsamling og andet, der udstikker retningslinjer...
4.2.2026, 13.18
af Salvelinus
18
Her er Anttis kommentarer, efter at Aiforia har lanceret en ny CE-IVD-mærket AI-løsning til diagnosticering af mavekræft. Aiforia meddelte mandag...
3.2.2026, 05.27
af Sijoittaja-alokas
16
Aiforias nye aktionærliste. Børsens guldhoved Timo Syrjälä er rykket op på en 41. plads. Aiforia Aiforia - Osakkeenomistajat Aiforia on lääketieteen...
2.2.2026, 19.59
af TO
17
Ja, man kan ikke direkte udlede Aiforias omsætning fra de forskellige løsninger baseret på kræftprocenterne. Det er faktisk mere sandsynligt...
2.2.2026, 16.24
af Vino Pino
10
De nye CE-IVD-mærkninger vil ikke nødvendigvis kunne ses i omsætningen i et stykke tid, men det øger markant potentialet for at blive et opk...
2.2.2026, 14.51
af Jekkku
7
Ubestrideligt ja, ved gastroskopi udtages der prøver fra flere steder i mavesækken samt tolvfingertarmen, hvilket betyder, at antallet af rutinem...
2.2.2026, 14.36
7
Jeg mener, at potentialet er meget større; jeg antager, at man med dette ville undersøge en betydelig del af PAD-prøverne fra maveslimhinden...
2.2.2026, 14.30
af Poimija
8
Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.